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ABSTRACT  The evidence relating the interferon system to the infectious proc-
ess  has  been  examined.  The  available  evidence  supports  the  view  that  the
interferon  system  is  an  important  component  of  the  body's  nonimmune  de-
fenses, which are probably the major causes of recovery from already established
virus  infections  of body  tissues.  The  interferon  system  can  also  serve  to limit
virus  spread through  the bloodstream.  Factors  which may influence  the inter-
feron system and thereby influence virus infection have been considered. Finally,
evidence  is  presented  which indicates  that the interferon  system is  one  of the
determinants  of virulence  of certain  viruses  and  is  one of the determinants  of
some  persistent virus infections.
The  discovery  of interferons  by  Isaacs  and  Lindenmann  (1)  led,  within  a
short time, to major revisions in concepts of cellular immunity and recovery of
multicellular  organisms from infection. The significance  of the antiviral effect
of the interferon  system extends to virus infections of the acute,  chronic,  and
oncogenic  varieties.  More recent  evidence suggests that the interferon system
may play a role during infection by Chlamydia and certain protozoal parasites.
This section will consider  the implications  of the interferon  system  as a  host
defense  during infection.  Several  reviews  contain  related information  (2-9).
A more detailed consideration  of the various  host defenses  during viral infec-
tion will be published  (10).
COMPONENTS  OF  THE  INTERFERON  SYSTEM
The term "interferon  system"  is used  because this anti-infectious  mechanism
is  now thought to be divisible  into several  components.  For the present pur-
poses we will refer to interferon  as a protein(s)  which is produced  or released
by cells following viral infection  and certain other stimuli. Available evidence
suggests that interferon is not itself directly antiviral,  but rather, it reacts with
cells to induce the formation of a new intracellular substance  which mediates
the antiviral activity.  This antiviral component of the interferon system may
be a polypeptide  or a protein.
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Production  of interferon  by the infected  cell  is thought  to be preceded  by
derepression  of the interferon  cistron, leading to formation of interferon mes-
senger RNA which then results in production of interferon protein.  Completed
interferon  is  rapidly  released  by  cells.  Production  of the proposed  antiviral
substance,  after  reaction  of  cells  with interferon,  is  similarly  thought  to  be
preceded by derepression  of another cistron and formation of messenger RNA
which is then  translated  into  a polypeptide.  There  is  little  evidence  to help
determine  whether  the  polypeptide  is  itself the  antiviral  substance  in  the
resistant cell, or whether it controls formation of an antiviral substance. Fig.  1
summarizes  these interactions.
The interferon  system  is the  earliest appearing  of the known host  defenses
in that  it can  be  detected  to be  operative  within  hours  after  infection  (3).
Most  viruses are  able to  induce  interferon  to  a greater  or  lesser extent,  and
most viruses are sensitive to its antiviral action also to a greater or lesser extent.
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FIGURE  1.  How interferon  works.  Current concepts of the mechanisms  of the interferon
system.
The antiviral action of interferon  is intracellular and may relate to an inhibi-
tion of the functioning  of the viral  messenger RNA  with the cells  ribosomes.
The duration of activation  of the interferon system (interference)  is from 1 to 3
wk during acute virus infections in vivo  (11-13).
The concepts  of the  sequential  formation  of the components  of the inter-
feron  system are presented  so they may serve as the basis for some  of the sub-
sequent interpretations.
ROLE  OF  INTERFERON  DURING  ESTABLISHMENT  OF
VIRAL  INFECTION  AT  THE  IMPLANTATION  SITE
Successful  infection  at the implantation  site requires  that viruses  replicate  in
the initially infected  cell and then spread  to infect other cells within the same
tissue.  The first host defense to make  its  appearance  is  the interferon system
(2,  3).  It  is produced by infected  cells at about the same  time as virus is pro-
produced.  Replication  of virus  in the  initially  infected  cell  is  probably not
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affected by the interferon system. The interferon mechanism which is activated
within  the  infected  cell probably does  not inhibit virus  infection  within that
cell.  This comes from the finding that inhibition of interferon  production  by
metabolic  inhibitors  in virus-infected  cells does not significantly  increase  the
virus yield  during a one-step growth  cycle  (14).
The interferon  protein  is released  from infected  cells  as it is  produced and
diffuses to surrounding cells where it activates  the production of the antiviral
state.  In  this way spreading virus meets an intracellular barrier to its contin-
ued replication.  The degree of antiviral  activity is probably dependent on the
extracellular  concentration  of interferon  (15),  so  the  cells  in closest  contact
with the infected,  interferon-producing  cells  become most resistant  to virus.
Protection of more distant cells does occur but to a lesser degree  (16,  17).  The
interferon  defense functions  in this manner  not only in infected  tissues  at the
portal of entry, but in any infected tissue as considered below.
Successful establishment of viral infection at the implantation site sometimes
leads to disease in that same tissue (e.g., influenza  infection of the lung, rhino-
virus  infection  of the  nasal  tract,  and  wart  virus  infection  of the  skin).  For
other  viruses the established  infection  at the  portal  of entry  serves  as a  dis-
semination site for spread  to other organs and tissues where  the disease  symp-
toms originate.
ROLE  OF  INTERFERON  DURING  SPREAD  OF  VIRUS
TO  DISTAL  TISSUES  AND  ORGANS
Virus may spread from the portal  of entry to target organs by means of body
fluid  (serum  or lymph)  or by means of infected  cells.  Interferon  appears  in
serum within a few hours after the onset of viremia (17).  Experiments utilizing
passive transfer  of interferon  indicate  that the circulating  interferon  can  act
to both reduce the viremia and to reach target organs where  it protects cells
against subsequent seeding of virus from the bloodstream and lymph (17-19).
Spread of virus may also occur via infected cells such as those in nerves  and
via white blood cells.  Spread of infection  along a nerve has not been studied in
terms  of the interferon  defense.  However  the possible  role  of the interferon
mechanism may be surmised from other knowledge.  Spread of virus along the
sheath surrounding the axon would be expected to be resisted in the same way
as  is virus spread during  early infection  of any tissues  (see  above).  Spread  of
virus  within  a  nerve  axon  could  be retarded  only  by intracellularly  active
defense  mechanisms.  The  interferon  defense  might  be  less  effective  in  this
situation because  activation  of the interferon  system would  be delayed  until
virus or interferon reaches the distant nucleus of the nerve cell to derepress the
cistron encoded  for antiviral protein.
Virus  may  also  spread  by infected white  blood  cells,  which,  due to  their
mobility,  could  deposit infectious  virus  in  target organs.  Several  of the host
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defenses  have  been  shown to affect the  ability  of leukocytes  to support virus
growth.  The lymphoid series of cells  in the body  are particularly sensitive to
the induction of interferon  in that a broad range of viral and nonviral stimuli
can  induce  these  cells.  The ready response  of interferon  production  has  also
provided  the first known  bridge between  the immunological  system  and the
interferon system and will be considered in the section by Dr. L. Glasgow.
ROLE  OF  INTERFERON  DURING  RECOVERY  FROM
THE  FULLY  ESTABLISHED  VIRUS  INFECTION  OF
BODY  TISSUES  AND  ORGANS
Virus may establish an infection  in various tissues within the body including
the implantation  site,  tissues in contact with the vascular  system,  and target
organs.  It  seems probable  that  the  mechanisms  which  govern  the  recovery
from the fully infected  tissue apply at these diverse  sites  of established  infec-
tion.  The recovery  process may not  occur simultaneously  within  the various
infected  tissues in the body because  the time of onset of infection  and time of
production  of  localized  host  defenses  is  usually  different  for  the  different
tissues.  In  this way, tissues  at the implantation site  or tissues in contact with
the vascular  system may be undergoing  recovery  at the time that virus infec-
tion is being established within  the target organs  (20-22).
The finding that a major characteristic of the recovering  tissue is nonspecific
resistance  to  viral  superinfection  indicates  that  nonimmune  defenses  like
interferon  are correlated temperally with recovery from the established  infec-
tion.  Fig.  2  schematizes  the  relative  occurrences  of  virus  growth,  disease,
interferon,  and antibody during  the first and during  a repeat infection.  Sup-
porting evidence  comes from many sources.
A  sufficient  quantity  of  interferon  can  inhibit  the  multiplication  of most
viruses in various animal tissues in vivo and in vitro (3).  Interferon  is generally
present in infected tissues of animals prior to the onset of recovery from diverse
virus infections (23-33).  Similar results have been obtained in studies in man
(8,  34).  These studies  have demonstrated  that interferon  can be produced  as
early  as  1 hr after  virus infection  and is  generally demonstrable  in high titer
within  1-2  days.  In  comparison,  recovery,  as measured  by decreasing  virus
in  the  infected  tissue,  usually  begins  1 or more  days  after  interferon  is  first
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FIGURE  2.  Host reaction  to viral infection.  Appearance  of virus,  interferon, and  anti-
body during  virus  infection.
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detected.  The presence  of interferon  in target  organs during recovery  is evi-
denced  by these same studies and also  by others (35-37).  Apparently,  incon-
sistent findings  are  the low or undetectable  levels  of interferon  in organs  of
mice  during  certain nonlethal  infections  (38-43).  But  some of these viruses
may  have  been  very  sensitive  to  interferon.  Hence,  interferon  produced  by
cells  originally  infected  may have so  reduced  virus  multiplication  that little
or  no detectable  amounts  of interferon  were formed  (44).  The finding  that
tissues  of  mice  which  were  chronically  infected  with  lymphocytic  chorio-
meningitis  virus  manifested  interference  in  the  absence  of  detectable  inter-
feron  (38)  suggests  either  the possibility  of  another  antiviral  factor,  or  that
the antiviral portion  of the interferon  system may have been  functioning  de-
spite the absence of detectable  interferon as discussed above.
Further evidence relating the interferon  system to recovery  comes from the
expectation  that  decreased  function  of  the  interferon  mechanism  would
increase  the severity  of those  virus infections  in  which it contributes  signifi-
cantly towards recovery.  Such were the findings in young chick embryos with
an "immature" interferon system (45). More recent studies have extended the
evidence.  Decreased  function  of the interferon  system,  as  caused  by altered
temperature,  psychological  stress,  chemical  inhibitors,  and  different  virus
strains, led to impaired recovery  of animals  (30, 46-49).  Carefully controlled
studies of tissue cultures infected with vaccinia, herpes, measles, or arboviruses
also  indicate that impairment  of the interferon  mechanism hinders  recovery
(50-54).
The effect of specific decrease in the functioning of the interferon mechanism
is  clearly  demonstrated  in studies of arbo  B virus  infection  of two  strains of
C3H  mice  (44).  C3H  and  C3H  RV mice  are known  to differ  only  at the
genetic  locus  which  determines  resistance  to infections  with  arbo B viruses.
They produce  equal  amounts  of interferon  after  arbo B  virus  infection,  but
the virus-resistant C3H RV cell cultures and the intact mice were much more
sensitive to the inhibitory  effect of interferon when tested with arbo B viruses
than were the C3H cultures or mice. The increased effectiveness  of interferon
was limited to arbo B viruses.  Thus a genetic  difference in interferon respon-
siveness determined  the severity  of virus infection both  in tissue  culture and
in the intact mouse. This study also points out the problem in interpreting the
role  of interferon  only  from  interferon  production  findings  (55),  since  cell
responsiveness to interferon can also be a determining factor.
Another  test of the relationship  of the interferon  system to recovery is the
transfer  of presently  available  amounts of interferon  to animals.  These  early
studies  demonstrated  greatest protection  when  interferon  was given prior  to
or at the same time as infection and not when interferon was given significantly
after infection  (56-63).  More recently treatment with large amounts of inter-
feron or inducers of interferon  was shown to retard the development of estab-
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lished  infections  with  encephalomyocarditis  virus,  leukemia  virus,  herpes
simplex  virus,  and  other viruses.  Analogously,  production  of interferon  by
virus-resistant  cells in a mixed tissue culture can protect the virus-susceptible
fraction  of the cell  population  (64).  The failure  of interferon to protect man
against  subsequent  rhinovirus  infection  (65),  unlike  the  previously  reported
protection against subsequent vaccinia virus infection (59), may have been due
to dosage problems.
Taken together most of the available  evidence  does  support a causal rela-
tionship  between  the interferon  system  and  recovery from  established  infec-
tions.  The  available  evidence  also  indicates  that  interferon  is  not  the  sole
factor which influences recovery,  and in certain virus infections it may not be
the most important  factor  (10).
INTERPLAY  OF  INTERFERON  WITH  OTHER  FACTORS
DURING  INFECTION
The possibility  has  been raised  that nonimmune  antiviral factors  may affect
the  interferon  system  as  well  as  directly  inhibit  virus  multiplication  (66).
Certain ones will be briefly considered here in relation to recovery from virus
infection.  For  example,  lowered  or raised temperature  may respectively  de-
press  or enhance the interferon  system during infections in vitro  and in vivo
(47,  53,  66,  67).  Changes  in pH  and oxygen  tension  have been reported  to
enhance or retard production of the interferon system in certain, but not all,
virus infections in vitro (68-72).
Other  mechanisms  may  also  affect  the  interferon  system.  Corticosteroids
have  been  reported  to inhibit  the interferon  system  in  several,  but  not  all,
virus infections in ovo and in vitro (73-75).  The effect of psychological  stress
on inhibiting production  of interferon  and increasing the severity  of vesicular
stomatitis virus  and polyoma virus infections  of mice may  have  a hormonal
basis (48).
It has been  observed that cells  and animals which have yielded  interferon
may  not yield  again for a period  of time on restimulation  by virus  (76-79).
Hyporeactivity to release of interferon by endotoxin may be due to a circulat-
ing inhibitor  of endotoxin  in  the rabbit  (77,  80).  The  significance or  hypo-
reactivity during virus infection is yet to be determined.
Another factor which has been reported to influence the interferon  system is
the age  of the  animal.  Tissues  from young  chick  and  mouse embryos  were
generally  found to  have  a poorly  functioning  interferon  system  (45,  81-83),
and this system  has been  shown in mice to continue  to develop  through the
neonatal  period  (84-85).  Several  of these  investigators  have  suggested  that
lack  of effectiveness  of the  immature  interferon  system  may  be  one  factor
which  contributes  to  the malforming  effects  of some  virus  infections  of the
fetus  and  to  unusually  severe  infections  during  the  neonatal  period  (7).  In-
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consistent  is the finding that lymphocytes from young human  embryos have
been  found  to  produce  normal  amounts  of  interferon  (K.  Cantell  and H.
Strander,  1969, personal communication.).
Results  of several  studies  have  indicated  that  pretreatment  of  cells  with
interferon influences the subsequent production  of interferon by infected cells
(86-88).  Chicken  and mouse  cells  treated  with small  amounts  of interferon
and then infected  with virus  produce  substantially more  interferon  than do
cells not previously treated with interferon. Pretreatment with large amounts
of  interferon  has  the reverse  effect  of decreasing  subsequent  production  of
interferon.  It  was  also  observed  that  chicken  cells  pretreated  with  small
amounts of interferon not only produced increased amounts of interferon after
infection, but they produced  interferon and  its messenger  RNA substantially
earlier  than  cultures  which had  not been  pretreated  (89,  90).  Such  an en-
hanced response bears a superficial resemblance  to an immunological  booster
effect and may similarly act to amplify the interferon defense mechanism.
Some  viruses  may  inhibit  the interferon  system by  causing  a  general  de-
pression  of the cellular RNA or protein synthesis which seems to be required
for production  of both interferon  and the proposed  antiviral  substance.  For
example,  mengo  virus  has  been  reported  to  produce  two  distinct  proteins
which respectively inhibit cellular synthesis of RNA and protein  (91).  Similar
inhibition  of  cellular  RNA  synthesis  following  infection  of cells  by  herpes
simplex  and  vesicular  stomatitis viruses  has  been correlated  with decreased
production  of interferon  (92,  93).  Inhibition  of the interferon  system before
production  of the antiviral  substance could  act to prevent  the action of this
antiviral mechanism.  However, prior establishment  of the antiviral effect has
been reported  to retard  the  virus-induced  inhibition  of cellular  synthesis  of
RNA  (94,  95).  The significance  of these phenomena  in relation to virulence
of viruses  and  pathogenesis  of infection  deserves  further  study.  It  also raises
the possibility  that infection  of an animal by a virus which inhibits synthesis
of components of the interferon system  could increase the severity of a subse-
quent infection by another virus.
A natural  experiment which illustrated  an interplay  of these  host defense
factors  is the human  disease  syndrome  hypogammaglobulinemia  (see  refer-
ence  7).  Impairment of production  of normal amounts of antibody  by these
patients  is  believed  to  result  in  increased  frequency  and  severity  of certain
pyogenic bacterial  infections as well  as a lesser increase in severity of certain
virus infections.  The small amount  of antibody produced by these patients is
sufficient to account for a resistance to the spread of many viruses through the
bloodstream  and,  therefore,  can  account  for  the  immunologically  specific
resistance to reinfection observed in these patients.  Since the nonimmune  and
nonspecific  defense  factors  are largely  independent  of the immune  response,
the  ability  of  hypogammaglobulinemic  patients  to  recover  normally  from
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established  virus  infection  is  probably  due  to  normally  functioning  cellular
immunity  (see  reference  7),  interferon  (96),  body  temperature  control,  in-
flammatory responses, etc. The occasionally observed increased severity of virus
infections  in  these patients  (e.g.  vaccinia  virus  and  poliomyelitis  infections)
might  be  explained  by  impaired  antibody  production  during  the  viremic
spread of virus in the primary infection with resulting  prolonged viremia and
increased  seeding of target organs.
THE  INTERFERON  SYSTEM  AS  A  FACTOR  IN  THE
VIRULENCE  OF  VIRUSES
If the interferon  system plays an important role in the body's defense against
virus infection, then it should be an important determinant of virus virulence
(97).  A virulent virus will be considered  as one which causes relatively  more
damage  to the  infected host  system  than do  other  strains  of the  same virus
type.
The  definition  of virus  sensitivity  to the antiviral  action  of interferon  be-
comes  critical  in  any  comparison  with virulence  of viruses.  Certain  viruses
like adenoviruses  (98,  99),  herpes viruses,  including  cytomegaloviruses  (100,
101),  have been considered to be relatively  resistant to the antiviral action of
interferon.  It recently  has  been  found  however  that  cell-free  human  cyto-
megalovirus is highly sensitive to the antiviral action of human interferon  (D.
Lang,  M. T. Thomas, and I. Gresser,  1969,  personal  communication).  Simi-
larly,  in  the mouse,  it has  been  found that  induction  of interferon protects
against very small  challenge  doses  of herpes  simplex virus  as well  as it does
against  small  or  large  doses  of  the  highly  sensitive  encephalomyocarditis
virus.  However,  there  is  no  protection  against  moderate  to  high  doses  of
herpes  virus  (102).  These  findings  indicate that  under certain  experimental
conditions cytomegalovirus  and herpes  simplex virus  may be highly sensitive
to the antiviral action of interferon.  It has been suggested that the production
of  anti-interferon  factors  (D.  Lang,  M.  T.  Thomas,  and  I.  Gresser,  1969,
personal  communication;  103,  104)  (see  below)  could  account  for  the dif-
ference in sensitivity under different experimental conditions.
A highly virulent virus should not be significantly  inhibited by any natural
defense factors  (including the interferon  system)  which  are active during in-
fection,  and/or the virulent virus should not  elicit these defensive  responses.
Consistent  with  this  interpretation  are  the observations  that  the  interferon
system  is relatively  ineffective in infections  with more virulent  strains of cer-
tain viruses,  and conversely,  the interferon system  is often more  effective  dur-
ing infections with less virulent viruses.  Supporting  data have been obtained
with  strains  of Newcastle  disease  virus  (67,  105),  vesicular  stomatitis  virus
(106),  Semliki  Forest  virus  (107),  rubella  virus  (108),  mumps  virus  (G.
Sharamek,  H.  Reploh,  and  F.  Deinhardt,  1969,  personal  communication),
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various  other arboviruses  (44,  67),  foot-and-mouth  disease  virus  (109),  and
polyoma virus (30).
It  has recently  been found that virulent  strains  of Newcastle  disease virus
induce little interferon  during infection  of chickens,  but that avirulent  strains
induce  larger  amounts  of interferon  during  infection  and at the same  time
manifest  a resistance  to superinfection  with Newcastle  disease  virus  (110).
As might be anticipated  from the existence  of a large number  of virus in-
hibitory  factors  in  addition  to  the  interferon  system  (111-113),  there  is  not
always  such a  correlation between  the response  of the interferon  system and
virulence,  e.g.,  with  strains  of  influenza  virus  (40,  42),  Sindbis  virus  (39),
Newcastle  disease virus  (105),  and vaccinia virus (41).  These reports are con-
sistent with multiple determinants of virus virulence.
Taken together,  the findings  are  consistent with the interpretation that the
interferon  system  may be  an important  determinant  of relative virulence  of
certain  virus strains. However,  definitive  studies must await development  of
techniques  for  the  simultaneous  measurement  of yield  of  virus,  interferon,
and antiviral activity per infected  cell, in vitro and at different stages of infec-
tion in the intact animal.
Recent observations  indicate  two additional mechanisms  whereby  a virus
may avoid the inhibitory  effect of the interferon system and, perhaps, thereby
manifest  increased virulence.  First, conditions  of infection by herpes  simplex
virus  (92)  and vesicular  stomatitis  virus  (93),  which  lead  to  inhibition  of
cellular RNA synthesis, suppress the synthesis of components of the interferon
system  while enhancing  yields  of virus.  The  phenomenon  of "inverse  inter-
ference"  (114) may have a similar basis. That inhibition of cellular RNA syn-
thesis  is not the  sole means by which  virus may cause decreased  production
of interferon  is  suggested  by the findings  that avirulent  strains  of Newcastle
disease  virus and parainfluenza  type 3 virus failed  to induce interferon  pro-
duction in cells, although no cytopathology occurred (105,  115,  116).  Absence
of cytopathology  suggests that there was no significant inhibition of RNA syn-
thesis during  the growth  of these viruses.  Mouse leukemia virus  and mouse
cytomegalovirus  infections  are  other  examples  (117,  118).  These  findings
indicate that certain cell-virus interactions do not lead to production  of much
interferon,  as a result  either  of inhibition by virus of cellular  synthetic  proc-
esses or  of unknown mechanisms.  The  relationship  between  ability  of virus
to inhibit  the  response of the interferon  system  and virulence  merits  further
study.
A  second mechanism  whereby virus may overcome  the inhibitory  effect  of
the interferon  system is the reported  existence  of a  fraction  of virus  popula-
tions which is resistant  (104,  119).  It was observed  that a fraction  of an  en-
cephalomyocarditis  virus population,  varying  from  10  to  15%  of the  input
virus, was capable  of multiplying in interferon-treated  mouse embryo cultures
(104).  The resistance  of this  "persistent  fraction"  to interferon  was  not due
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to  a  genetic  property  of  the  virus,  and  superficially  it  resembled  similar
phenomena observed with most other virus-inactivating agents  (120).  Vesicu-
lar stomatitis virus  and vaccinia  virus were also shown to contain interferon-
resistant  persistent  fractions.  The magnitude  of the persistent  fraction  may
vary depending  on the virus,  type  of cell,  as well as  on the cellular environ-
ment. A large persistent fraction  of this type could exert an  important influ-
ence  on virulence  of infection,  but  such  studies are yet  to be carried  out in
vivo.
ROLE  OF  THE  INTERFERON  SYSTEM  IN  PERSISTENT
INFECTIONS
Persistent infection in vitro and in vivo may result from infection of genetically
resistant  cells,  from antibody or other  virus inhibitors in extracellular  fluids,
from  interference  and  interferon,  and  from  unknown  factors  (121).  Several
persistent  infections  of tissue cultures  are thought  to be caused  by the inter-
feron system,  although only  a few  definitive studies  have been  reported.  In-
terferon  has been  detected  at very early and at advanced  stages of persistent
infection  of mouse  L  cells  with Newcastle  disease  virus  (122-124),  human
amnion  and  KB cells  with poliovirus  (125),  calf kidney  cells  with  the WS
strain  of influenza  virus  and  with foot-and-mouth  disease  virus  (126,  127),
KB cells with parainfluenza  type 3 virus  (128),  mouse embryo cells with vac-
cinia virus (50), human amnion and mouse L cells with tick-borne encephalitis
virus  (53,  129),  mouse 23 P cells with polyoma virus and with herpes simplex
virus (90), and monkey cells with rubella virus (130).  Similar results have been
observed during the early period of infection of mice with lactic  dehydrogen-
ase virus (32).  Interferon was found during the later stages of persistent infec-
tion of mouse  cell  cultures  with polyoma viruses;  tests for it were not made
during the early stages  (131).  Neither interferon  nor significant  interference
of the interferon type  was detected  in mouse  L-cell  cultures  persistently  in-
fected  with polyoma  virus  (123,  132),  in  chicken  cells  infected  with  RAV
leukosis virus (133),  or in mouse cells infected with murine leukemia viruses
(134),  suggesting that the interferon  system did not participate in the mainte-
nance of these carrier cultures.  Persistent infections of mice or of mouse L-cell
cultures with lymphocytic choriomeningitis  virus did  not give rise to detect-
able interferon but did result in interference  (38).  However,  the precise times
of sampling of these persistently  infected mice were not stated, and it is possi-
ble that interferon  was produced during the initial stages  of infection  as it is
during  infection  with  lactic  dehydrogenase  virus.  The  demonstration  of
interference  when no or only low levels of interferon can be detected does not
exclude  an important  role  for the interferon  system  during  these  persistent
infections.  It  is conceivable  that  (a.)  the rapid  turnover  rate of interferon in
vivo  (17,  19,  135)  reduces levels below detectability,  or (b) intracellular inter-
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feron in  amounts which cannot be detected  may still be highly effective  (53,
136).
Further evidence linking the interferon system to persistent infections comes
from  studies  of inhibition  or  enhancement  of  the  interferon  system  during
persistent  infections.  Enhancement  of  the  interferon  mechanism  retarded
multiplication of vaccinia virus, herpes simplex virus, and tick-borne encepha-
litis  virus  during  persistent  infections  in  mouse  cell  cultures  (50,  53,  88).
Similarly  in mice,  stimulation  of the interferon  system inhibited the growth
of lactic  dehydrogenase  virus  (137).  Conversely,  inhibition  of the interferon
mechanism by several techniques was followed by enhanced  virus growth and
increased cell destruction  in persistently  infected  mouse cell cultures  (50,  53,
88). In general,  the resistance of persistently infected cultures was nonspecific
for  virus-a  property  coinciding  with  that  of  the  interferon  system.  The
quantity  of interferon was shown to be sufficient to account for the observed
inhibition of herpes simplex virus during persistent infection of mouse cell cul-
tures with both herpes  simplex and polyoma viruses  (88).  Studies with other
viruses  and  cells  are  needed  to  establish  that  the  antiviral  activity  of the
interferon  system  is  quantitatively  sufficient  to  account  for persistent  infec-
tions.  Another  difficulty  is  that  certain  persistently  infected  cell  cultures
which  manifest  interference  produce  interferon  but  are  not sensitive  to  the
action  of exogenous  interferon  (53,  125,  128,  129).  It  is  possible  that  the
interferon produced within the infected  cells is better able to induce the anti-
viral state than is exogenous  interferon.
Several  of these  investigators  and  others  (138)  have suggested  that those
persistent  infections which are dependent upon the interferon system may re-
sult from a shifting balance between antiviral activity and virus multiplication.
Specifically, increasing multiplication  of virus in a persistently infected  system
induces  increased  production  of interferon  and  antiviral activity, which pre-
vents further increase  of virus.  Conversely,  decreasing  multiplication  of virus
results in  decreased  interferon and  antiviral activity,  which then  permits in-
crease of virus multiplication.
That the  interferon  system  may  be  participating  in  naturally  occurring
persistent  infections  comes from several  studies.  Interferon was produced  by
cultured cells from three different cases of human malignant lymphoma  (139,
140).  Herpes  simplex virus-like  particles  are  frequently  found  in  these cells
by  electron microscopy  (141).  Another  example  is the observation  that cul-
tures from normal chick embryos can initiate production  of interferon  (R. Z.
Lockart, Jr., and T. Sreevalsan,  1965,  personal communication).  Since many
flocks of chickens  are persistently infected with leukosis viruses  (142) and per-
haps other viruses, it is possible that the interferon production resulted from a
persistent  infection in ovo.
Taken together,  the available  evidence  favors the view  that the interferon
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system  is  an  important  determinant  of certain  persistent  infections  in  vitro
and in vivo.  However,  further studies  are needed  to determine  what propor-
tion of persistent infections it influences.
APPLICATION  TO  CONTROL  OF  VIRAL  DISEASE
Medical  science  has very  effectively  adapted  the  natural  antibody  defense
against viral spread and reinfection to prevent but not to treat viral infections.
The  natural  antibody  defense  is  nontoxic,  and  so  application  has  been
achieved with minor problems of toxicity.  Antibody  has been  applied to dis-
ease prophylaxis both by passive transfer of antibody and by vaccine stimula-
tion of antibody. However, a major limitation of the application of the antibody
defense is a lack of effectiveness  of antiviral antibody  after the establishment
of infection  of the target  organs.  A  classic  example  is  the  ability  of  anti-
body  to  prevent  measles  infection  of  children  when  the antibody  is  given
early after exposure to virus, but as the incubation period of measles progresses
the amount  of antibody required  to influence the oncoming disease increases
rapidly.  Towards  the end of the incubation  period  of measles  no amount  of
antibody  provides  protection.  Thus  antibody  against  measles  virus  loses  its
effectiveness  as the onset of the established  disease approaches.
By analogy it had been predicted  that the interferon defense system which
is  thought  to naturally  promote  recovery  could  be applied  to  both prevent
and treat virus infection  (c.f.  2,  3,  7,  9,  143-145).  Also,  as  a natural  defense
mechanism,  toxicity  should  be  minimal.  It has  already  been  demonstrated
that interferon can prevent a broad range of virus infections.  However,  until
recently the limitation of the quantity of interferon  which could be produced
and the species barrier to the action of interferon  have prevented  therapy  of
established  infections  (145).  These  limitations  have  also  prevented practical
prophylaxis  of viral  infections  of man.  As  a  result  many  studies  have  con-
centrated  on the development of chemicals which induce the body to produce
large amounts of its own interferon.  Beginning with Isaacs  and  his  coworkers
(68),  it has been shown that such inducers can be found and that some of them
are  relatively  nontoxic  and  inexpensive.  These  inducers  include  extracts  of
microorganisms,  such as statolon (146).  Also included are the synthetic pyran
copolymers  (147)  and  natural  and  synthetic  ribonucleic  acids  (148,  149).
Certain  of  the  RNA  inducers  of the  interferon  mechanism  are  extremely
potent.  The  therapeutic  efficacy  of  RNA  inducers  of  interferon  in  herpes
keratoconjunctivitis  has been studied  (150)  (Fig. 3).  Fig.  3 shows that rabbits
with  herpes  infections  of  the eye  may  be  treated  with  interferon  inducers
after establishment  of the disease with resulting enhanced  recovery  from the
infection.
Quite  recently  it has  been  found  that inducers  of interferon  will  protect
against certain protozoal  parasites  (151-153).  This aspect will be considered
in this  session by Dr. Jahiel.
204  sS.  BARON  Defensive Role of Interferon
FIGURE  3.  Response  of herpe-
tic  keratoconjunctivitis  to  top-
ical  treatment  with  polyino-
sinic:polycytidylic  acid.  R.
indicates treatment.
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It has been reported  that the interferon inducer, polyinosinic: polycytidylic
acid (154) inhibits the growth of a number of experimental  tumors in animals.
Most  of the tumor types  were not deliberately  induced by virus, but rather,
they were transplanted  tumors of spontaneous  origin or induced  by chemical
carcinogenesis  (154-158).  This compound,  in addition to inducing interferon,
enhances  cell mediated  graft vs.  host reactions  and may have direct  specific
chemotherapeutic  action  against some of the tumors.  It  is not yet clear  how
much of the antitumor  action is  attributable  to the interferon system,  but it
should be pointed out that it has also been shown that interferon preparations
exert strong antitumor action when tested against tumors of virus origin (159),
and even  against tumors induced by a chemical carcinogen  (160).
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